Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04028531 · ClinicalTrials.gov registry record
Understanding Chronic Lymphocytic Leukemia
A clinical trial of Chronic Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 2,750
- Enrollment target
- 1
- Study location
NCT04028531: Recruiting study of Chronic Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT04028531 is a study of Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 2,750 participants, above the 167-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (1547% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04028531, a study of Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 2,750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Primary Outcome
Exploratory science to better understand Chronic Lymphocytic Leukemia
Conditions Studied
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,750 participants |
| Start Date | 1999-09-29 |
| Est. Completion | 2032-09-29 |
What NCT04028531 shows while recruiting
NCT04028531 is an observational study that tracks outcomes without assigning an intervention. Its 2,750 participants enrollment target places it among the larger protocols in the corpus, above the 167-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (1547% higher).
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT04028531 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04028531 about?
NCT04028531 is a clinical study titled "Understanding Chronic Lymphocytic Leukemia". The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
What is the current status of trial NCT04028531?
This trial is currently recruiting. The enrollment target is 2,750 participants. The study started on 1999-09-29. Estimated completion is 2032-09-29.
What conditions does trial NCT04028531 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
Who is sponsoring clinical trial NCT04028531?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04028531 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04028531's enrollment target sits among peer trials
2,750 1st of 187 higher than 187 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI